Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024)

NovaBridge Biosciences (NBP) reported Capital Expenditures of -$38000.0 for Q4 2024, down 3700.0% on a QoQ basis from -$1000.0 in Q3 2024.

NovaBridge Biosciences (NBP) has 3 years of Capital Expenditures data on file, last reported at -$38000.0 in Q4 2024.

  • Quarterly Capital Expenditures changed N/A year-over-year to -$38000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$39000.0 (down 100.91% YoY) and the FY2025 annual result came in at -$7000.0, up 85.42% from the prior year.
  • Capital Expenditures slipped to -$38000.0 in Q4 2024 per NBP's latest filing, from -$1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.9 million in Q4 2020 and bottomed at -$38000.0 in Q4 2024.

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -38,000.00
Dec 31, 2024 -38,000.00
Sep 30, 2024 -1,000.00
Sep 30, 2024 -1,000.00
Dec 31, 2020 1.93 Mn
Dec 31, 2020 1.93 Mn
Dec 31, 2019 2.39 Mn
Dec 31, 2019 2.39 Mn